Geron to Participate in the Baird 2023 Global Healthcare Conference
- Geron CEO's participation at the conference could positively impact investor sentiment
- None.
A webcast of the presentation will be available through the Investors and Media section of Geron’s website under Events following the presentation. The webcast will be archived and available for replay for a period of 30 days.
About Geron
Geron is a late-stage biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies. Our first-in-class investigational telomerase inhibitor, imetelstat, harnesses Nobel Prize-winning science in a treatment that may alter the underlying drivers of disease. The New Drug Application (NDA) for imetelstat in lower risk myelodysplastic syndromes (LR MDS), based on the results from the Phase 3 IMerge clinical trial, is currently under review by the United States Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June 16, 2024. Additionally, Geron currently has an ongoing pivotal Phase 3 clinical trial evaluating imetelstat in relapsed/refractory myelofibrosis (MF). To learn more, visit www.geron.com or follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230905077509/en/
Aron Feingold
Vice President, Investor Relations and Corporate Communications
Kristen Kelleher
Senior Manager, Investor Relations
investor@geron.com
media@geron.com
Source: Geron Corporation